Key result
The synergistic combination of Valproic acid and Zebularine inhibited colon cell proliferation and increased KLF4 expression by 2-fold in SW480 cells and 22-fold in DLD-1 cells.
Why the study?
Colorectal cancer is a leading cause of global mortality driven by abnormal regulation of oncogenes and deactivation of tumor suppressor genes, necessitating effective drugs targeting these genes.
Population
Early-stage (SW480) and late-stage (DLD-1) colon cancer cells
Comparison
Valproic acid and Zebularine combined vs independent doses
Design
In-vitro preclinical study
Authors
Loading...
Hypothesis-generating for VPA+ZEB in colorectal cancer; leaves open clinical translation pending trials.
The combination of VPA and ZEB shows potential as an anti-colon cancer agent by modulating KLF4 and CTNNB1 expression in vitro.
Kandhavelu et al. (2026) studied Colorectal cancer. Valproic acid (VPA) and Zebularine (ZEB) vs. Independent doses was evaluated on Cell proliferation and expression of KLF4 and CTNNB1. The synergistic combination of Valproic acid and Zebularine inhibited colon cell proliferation and increased KLF4 expression by 2-fold in SW480 cells and 22-fold in DLD-1 cells.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: